Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Terjung, C."'
Autor:
Vakalopoulos A; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Basting D; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Brechmann M; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany.; CSL Innovation GmbH, Emil-von-Behring-Str. 76, Marburg 35041, Germany., Teller H; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany.; micromod Partikeltechnologie GmbH, Schillingallee 68, Rostock 18057, Germany., Boultadakis Arapinis M; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Straub A; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Mittendorf J; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Meininghaus M; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Müller T; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Nowak-Reppel K; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Schäfer M; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany.; Nuvisan ICB GmbH, Müllerstrasse 178, Berlin 13353, Germany., Wittwer M; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany.; F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland., Kullmann M; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany.; BioNTech SE, An der Goldgrube 12, Mainz 55131, Germany., Terjung C; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Lang D; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Poethko T; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Marquardt T; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Freudenberger T; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Mondritzki T; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany.; University of Witten/Herdecke, Witten 58455, Germany., Hüser J; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany.; Axxam S.p.A., Openzone - Via Meucci 3, Bresso, Milan 20091, Italy., Heckmann M; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany., Tinel H; Bayer AG, Pharmaceuticals, Research and Development, Aprather Weg 18a, Wuppertal 42113, Germany.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Nov 14; Vol. 67 (21), pp. 19165-19187. Date of Electronic Publication: 2024 Oct 28.
Autor:
He MM; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.) he_michelle_minxia@lilly.com xiaochun.zhu@takeda.com., Zhu SX; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.) he_michelle_minxia@lilly.com xiaochun.zhu@takeda.com., Cannon JR; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Christensen JK; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Duggal R; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Gunduz M; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Hilgendorf C; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Hughes A; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Kekessie I; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Kullmann M; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Leung D; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Terjung C; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Wang K; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.)., Wesche F; Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.M.H.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.X.Z.); Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Princeton, New Jersey (J.R.C.); Development ADME, Novo Nordisk A/S, Måløv, Denmark (J.K.C.); Preclinical Development ADME, Merck & Co., Boston, Massachusetts (R.D.); PK Sciences/Global Biotransformation, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts (M.G.); DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden (C.H.); Discovery Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Stevenage, United Kingdom (A.H.); Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California (I.K.); Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany (M.K., C.T.); Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, California (D.L.); Translational PK/PD and Investigative Toxicology, Janssen Research & Development, San Diego, California (K.W.); and Department of Drug Discovery Sciences, Discovery Science Technology Group, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany (F.W.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Nov; Vol. 51 (11), pp. 1436-1450. Date of Electronic Publication: 2023 Aug 17.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Schubert W; Former employee, Bayer AG, Wuppertal, Germany., Terjung C; Bayer AG, Wuppertal, Germany., Rafique A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Romano C; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Ellinger P; Bayer AG, Wuppertal, Germany., Rittenhouse KD; Bayer Consumer Care AG, Basel, Switzerland.
Publikováno v:
Translational vision science & technology [Transl Vis Sci Technol] 2022 Oct 03; Vol. 11 (10), pp. 36.
Publikováno v:
Sozialer Sinn; 2023, Vol. 24 Issue 2, p211-221, 11p
Autor:
Bah GS; Institut de Recherche Agricole pour le Développement, Centre Régional de Wakwa, Ngaoundéré, Cameroun., Schneckener S; Bayer AG, Engineering & Technology, Applied Mathematics, Leverkusen, Germany., Hahnel SR; Bayer Animal Health GmbH, Drug Discovery & External Innovation, Monheim am Rhein, Germany., Bayang NH; Institut de Recherche Agricole pour le Développement, Centre Régional de Wakwa, Ngaoundéré, Cameroun., Fieseler H; Bayer Animal Health GmbH, Drug Discovery & External Innovation, Monheim am Rhein, Germany., Schmuck GM; Bayer Animal Health GmbH, Drug Discovery & External Innovation, Monheim am Rhein, Germany., Krebber R; Bayer AG, Crop Science Division, Research & Development-Regulatory Science-Human Safety-Residue Analysis, Monheim am Rhein, Germany., Sarr A; INVENesis Sarl, St-Blaise (NE), Switzerland., Terjung C; Bayer AG, Pharmaceuticals, DMPK, Wuppertal, Germany., Ngangyung HF; Institut de Recherche Agricole pour le Développement, Centre Régional de Wakwa, Ngaoundéré, Cameroun., Ekale DD; Institut de Recherche Agricole pour le Développement, Centre Régional de Wakwa, Ngaoundéré, Cameroun., Mfopit YM; Institut de Recherche Agricole pour le Développement, Centre Régional de Wakwa, Ngaoundéré, Cameroun., Rufener L; INVENesis Sarl, St-Blaise (NE), Switzerland., Graham-Brown J; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom., Tanya VN; Institut de Recherche Agricole pour le Développement, Centre Régional de Wakwa, Ngaoundéré, Cameroun.; Cameroon Academy of Sciences, Yaoundé, Cameroon., Glenschek-Sieberth M; Bayer AG, Pharmaceuticals, Wuppertal, Germany., Kulke D; Bayer Animal Health GmbH, Drug Discovery & External Innovation, Monheim am Rhein, Germany., Makepeace BL; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.
Publikováno v:
PLoS pathogens [PLoS Pathog] 2021 Jun 02; Vol. 17 (6), pp. e1009601. Date of Electronic Publication: 2021 Jun 02 (Print Publication: 2021).
Autor:
Beck H; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Thaler T; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Meibom D; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Meininghaus M; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Jörißen H; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Dietz L; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Terjung C; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Bairlein M; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., von Bühler CJ; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Anlauf S; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Fürstner C; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Stellfeld T; Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany., Schneider D; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Gericke KM; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Buyck T; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Lovis K; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Münster U; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Anlahr J; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Kersten E; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Levilain G; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Marossek V; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany., Kast R; Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2020 Oct 22; Vol. 63 (20), pp. 11639-11662. Date of Electronic Publication: 2020 Oct 08.
Miniaturized analytical chip devices like biosensors nowadays provide assistance in highly diverse fields of application such as point-of-care diagnostics and industrial bioprocess engineering. However, upon contact with fluids, the sensor requires a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::96677f04b1877887d3767a4d4c0cad31
https://publica.fraunhofer.de/handle/publica/237287
https://publica.fraunhofer.de/handle/publica/237287
Autor:
Hui Q; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China., Karlstetter M; Bayer AG, Wuppertal, Germany., Xu Z; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Yang J; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China., Zhou L; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Eilken HM; Bayer AG, Wuppertal, Germany., Terjung C; Bayer AG, Wuppertal, Germany., Cho H; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Gong J; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Lai MJ; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Nassar K; Bayer AG, Wuppertal, Germany. Electronic address: khaled.nassar@bayer.com., Duh EJ; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: eduh@jhmi.edu.
Publikováno v:
Free radical biology & medicine [Free Radic Biol Med] 2020 Jan; Vol. 146, pp. 181-188. Date of Electronic Publication: 2019 Nov 07.
Autor:
Lerchen HG; Bayer AG R&D Pharmaceuticals, Aprather Weg 18a, 42113, Wuppertal, Germany., Wittrock S; Bayer AG R&D Pharmaceuticals, Berlin, Germany., Stelte-Ludwig B; Bayer AG R&D Pharmaceuticals, Aprather Weg 18a, 42113, Wuppertal, Germany., Sommer A; Bayer AG R&D Pharmaceuticals, Berlin, Germany., Berndt S; Bayer AG R&D Pharmaceuticals, Berlin, Germany., Griebenow N; Bayer AG Animal Health, Lead Discovery, Monheim, Germany., Rebstock AS; Bayer AG Crop Science, Lyon, France., Johannes S; Bayer AG R&D Pharmaceuticals, Aprather Weg 18a, 42113, Wuppertal, Germany., Cancho-Grande Y; Bayer AG R&D Pharmaceuticals, Aprather Weg 18a, 42113, Wuppertal, Germany., Mahlert C; Bayer AG R&D Pharmaceuticals, Aprather Weg 18a, 42113, Wuppertal, Germany., Greven S; Bayer AG R&D Pharmaceuticals, Aprather Weg 18a, 42113, Wuppertal, Germany., Terjung C; Bayer AG R&D Pharmaceuticals, Aprather Weg 18a, 42113, Wuppertal, Germany.
Publikováno v:
Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2018 Nov 12; Vol. 57 (46), pp. 15243-15247. Date of Electronic Publication: 2018 Oct 15.